Molecular targets of natural drug substances: Idiosyncrasies and preferences

Planta Medica

Volumn 76, Issue 16, 2010, Pages 1794-1801

  Imming, Peter ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

drug substances; molecular mechanisms; natural products; target classes

Indexed keywords

ALKALOID; ANSAMYCIN DERIVATIVE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; CHLORAMPHENICOL; CYTOKINE RECEPTOR; DIHYDROFOLATE REDUCTASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; HORMONE; HYDROLASE; IMMUNOSUPPRESSIVE AGENT; INTEGRIN RECEPTOR; ION CHANNEL; ISOMERASE; LIGASE; LYASE; NATURAL PRODUCT; NUCLEIC ACID; NUTRACEUTICAL; OXIDOREDUCTASE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL; RIBOSOME PROTEIN; THIAZIDE DIURETIC AGENT; TRANSFERASE; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

BACTERIAL METABOLISM; COMBINATORIAL CHEMISTRY; DRUG BINDING; DRUG MECHANISM; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; ION EXCHANGE; MITOSIS; MITOSIS SPINDLE; NONHUMAN; REVIEW;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PHARMACOLOGY;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 78349275387     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0030-1250236     Document Type: Review

References (51)

1. Buckingham J. Dictionary of natural products. London Chapman and Hall/CRC Press 2001
2. Overington J P., Al-Lazikani B, Hopkins A L. How many drug targets are there? Nat Rev Drug Discov 2006 5 993-996
3. Li J W. H., Vederas J C. Drug discovery and natural products: end of an era or an endless frontier? Science 2009 325 161-165
4. Feher M, Schmidt J M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2003 43 218-227
5. Grabowski K, Schneider G. Properties and architecture of natural products revisited. Curr Chem Biol 2007 1 115-127
6. Grabowski K, Baringhaus K H., Schneider G. Scaffold diversity of natural products: inspiration for combinatorial library design. Nat Prod Rep 2008 25 892-904
7. Lowe D. In the pipeline. Derek Lowe is looking for a little more variety among his reactions. Chem World 2008 5 18
8. Redwan el-RM. Animal-derived pharmaceutical proteins. J Immunoassay Immunochem 2009 30 262-290
9. Oehler C, Bensdorf K, Gust R, Imming P. Chamavioline antiedematous, but not a constituent of Matricaria recutita. Phytochem Lett 2009 2 171-175
10. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006 5 821-834
11. Gwilt P G., Gwilt J R. Dame Agatha's poisonous pharmacopoeia. A chronological list of Agatha Christie stories which involved poison. Pharmacol J 1978 221 572-573
12. Swinney D C. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 2004 3 801-808
13. Swinney D C. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 2009 12 31-39
14. Rosenbaum D M., Rasmussen S G., Kobilka B K. The structure and function of G-protein-coupled receptors. Nature 2009 459 356-363
15. Vaugeois J M. Signal transduction: positive feedback from coffee. Nature 2002 418 734-736
16. Agnati L F., Fuxe K, Ferré S. How receptor mosaics decode transmitter signals. Possible relevance of cooperativity. Trends Biochem Sci 2005 30 188-193
17. Heien M L., Khan A S., Ariansen J L., Cheer J F., Phillips P E., Wassum K M., Wightman R M. Real-time measurement of dopamine fluctuations after cocaine in the brain of behaving rats. Proc Natl Acad Sci USA 2005 102 10023-10028
18. Patrignani P, Tacconelli S, Sciulli M G., Capone M L. New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev 2005 48 352-359
19. Chulia S, Ivorra M D., Martinez S, Elorriaga M, Valiente M, Noguera M A., Lugnier C, Advenier C, D'Ocon P. Relationships between structure and vascular activity in a series of benzylisoquinolines. Br J Pharmacol 1997 122 409-416
20. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004 9 641-651
21. Wermuth C G. Selective optimization of side activities: the SOSA approach. Drug Discov Today 2006 11 160-164
22. Payne D J., Gwynn M N., Holmes D J., Pompliano D L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007 6 29-40
23. Drews J, Ryser St. Molecular drug targets. Nat Biotechnol 1997 15 1350
24. Hopkins A L., Groom C R. The druggable genome. Nat Rev Drug Discov 2002 1 727-730
25. Golden J B. Prioritizing the human genome: Knowledge management for drug discovery. Curr Opin Drug Discov Devel 2003 6 310-316
26. Golden J. Towards a tractable genome: knowledge management in drug discovery. Curr Drug Discov 2003 3 17-20 (Pubitemid 36231317)
27. Wishart D S., Knox C, Guo A C., Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006 43 D668-D672
28. Wishart D S., Knox C, Guo A C., Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008 36 D901-D906
29. Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, Huang L, Guo Y, Han L, Zheng C, Chen Y. Update of TTD. Nucleic Acids Res 2010 38 (Database issue) D787-D791 http://xin.cz3.nus.edu.sg/group/cjttd/TTD-ns.asp
30. Li J J. Triumph of the heart: the story of statins. Oxford Oxford University Press 2009
31. Brown A G., Smale T C., King T J., Hasenkamp R, Thompson R H. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc [Perkin I] 1976 1165-1170
32. Bizukojc M, Ledakowicz S. Physiological, morphological and kinetic aspects of lovastatin biosynthesis by Aspergillus terreus. Biotechnol J 2009 4 647-664
33. Greenwood D. The quinine connection. J Antimicrob Chemother 1992 30 417-427
34. Kohanski M A., Dwyer D J., Hayete B, Lawrence C A., Collins J J. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007 130 797-810
35. Ganesan A. The impact of natural products upon modern drug discovery. Curr Opin Chem Biol 2008 12 306-317
36. Lipinski C A. Chemistry after the rule of five. Drug Discov Today 2003 8 12-16
37. Shen T Y. Perspectives in nonsteroidal anti-inflammatory agents. Angew Chem Int Ed Engl 1972 11 460-472
38. Adams S S. The propionic acids: a personal perspective. J Clin Pharmacol 1992 32 317-323
39. de Sá Alves F R., Barreiro E J., Fraga C A. From nature to drug discovery: the indole scaffold as a 'privileged structure'. Mini Rev Med Chem 2009 9 782-793
40. Wu Y D., Gellman S. Peptidomimetics. Acc Chem Res 2008 41 1231-1232
41. Corey E J., Niwa H, Falck J R., Mioskowski C, Arai Y, Marfat A. Recent studies on the chemical synthesis of eicosanoids. Samuelsson B, Ramwell PW, Paoletti R Advances in prostaglandin and thromboxane research, Vol. 6. New York Raven Press 1980 19-25
42. Deorukhar A, Krishnan S, Sethi G, Aggarwal B B. Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs 2007 16 1753-1773
43. Hyman S E., Fenton W S. What are the right targets for psychopharmacology? Science 2003 299 350-351
44. Barry III C E., Matter A. Next-generation therapeutics: Turning the current 'innovation gap' into an 'innovation leap'. Curr Opin Chem Biol 2006 10 291-293
45. Lennox J. God's undertaker: has science buried god? Oxford (UK) Lion Hudson 2009
46. Polkinghorne J C. Belief in god in an age of science. New Haven, CT Yale University Press 2003
47. Cragg G M., Newman D J., Snader K M. Natural products in drug discovery and development. J Nat Prod 1997 60 52-60
48. Newman D J., Cragg G M., Snader K M. Natural products as sources of new drugs over the period 19812002. J Nat Prod 2003 66 1022-1037
49. Baker D D., Chu M, Oza U, Rajgarhia V. The value of natural products to future pharmaceutical discovery. Nat Prod Rep 2007 24 1225-1244
50. Butler M S. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 2008 25 475-516
51. Raffin-Sanson M L., de Keyzer Y, Bertagna X. Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions. Eur J Endocrinol 2003 149 79-90